Ahle Guido, Touitou Valérie, Cassoux Nathalie, Bouyon Marie, Humbrecht Catherine, Oesterlé Hélène, Baraniskin Alexander, Soussain Carole, Nguyen-Them Ludovic, Gaultier Claude, Hoang-Xuan Khê, Houillier Caroline
Service de Neurologie, Hôpitaux Civils de Colmar, Colmar, France.
Service d'Ophtalmologie, Hôpital Pitié-Salpêtrière, Paris, France.
JAMA Neurol. 2017 Nov 1;74(11):1368-1373. doi: 10.1001/jamaneurol.2017.2545.
Visual impairment in primary central nervous system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous involvement (vitritis and retinal infiltration), whereas optic nerve infiltration (ONI) is a rare condition.
To describe the clinical presentation of ONI, its imaging characteristics, and outcome.
DESIGN, SETTING AND PARTICIPANTS: A total of 752 patients diagnosed with PCNSL were retrospectively identified from the databases of 3 French hospitals from January 1, 1998, through December 31, 2014. Of these, 7 patients had documented ONI. Exclusion criteria were intraocular involvement, orbital lymphoma, or other systemic lymphoma. Clinical presentation, neuroimaging, biological features, treatment, and outcomes were assessed.
Treatment response was evaluated clinically and radiologically on follow-up magnetic resonance imaging (MRI) according to the International PCNSL Collaborative Group response criteria.
The 7 patients included 5 women and 2 men. Median age at diagnosis was 65 years (range, 49-78 years). Two patients had initial ONI at diagnosis, and 5 had ONI at relapse. Clinical presentation was marked by rapidly progressive and severe visual impairment for all patients. The MRI findings showed optic nerve enlargement in 3 patients and contrast enhancement of the optic nerve in all patients. Additional CNS lesions were seen in 4 patients. Examination of cerebrospinal fluid samples detected lymphomatous meningitis in 2 patients. Clinical outcome was poor and marked by partial recovery for 2 patients and persistent severe low visual acuity or blindness for 5 patients. Median progression-free survival after optic nerve infiltration was 11 months (95% CI, 9-13 months), and median overall survival was 18 months (95% CI, 9-27 months).
Optic nerve infiltration is an atypical and challenging presentation of PCNSL. Its visual and systemic prognosis is particularly poor compared with vitreoretinal lymphomas even in response to chemotherapy. Although intraocular involvement is frequent in PCNSL and clinically marked by slowly progressive visual deterioration, lymphomatous ONI is rare and characterized by rapidly progressive severe visual impairment.
原发性中枢神经系统淋巴瘤(PCNSL)导致的视力损害主要由眼内淋巴瘤累及(葡萄膜炎和视网膜浸润)引起,而视神经浸润(ONI)则较为罕见。
描述ONI的临床表现、影像学特征及预后。
设计、地点和参与者:从法国3家医院1998年1月1日至2014年12月31日的数据库中,回顾性确定了752例诊断为PCNSL的患者。其中,7例有记录在案的ONI。排除标准为眼内累及、眼眶淋巴瘤或其他系统性淋巴瘤。评估临床表现、神经影像学、生物学特征、治疗及预后。
根据国际PCNSL协作组的反应标准,在随访磁共振成像(MRI)上从临床和影像学角度评估治疗反应。
7例患者中,5例女性,2例男性。诊断时的中位年龄为65岁(范围49 - 78岁)。2例患者在诊断时初发ONI,5例在复发时出现ONI。所有患者的临床表现均为迅速进展的严重视力损害。MRI表现为3例患者视神经增粗,所有患者视神经均有强化。4例患者还发现了其他中枢神经系统病变。脑脊液样本检查发现2例患者有淋巴瘤性脑膜炎。临床预后较差,2例患者部分恢复,5例患者持续严重低视力或失明。视神经浸润后的中位无进展生存期为11个月(95%CI,9 - 13个月),中位总生存期为18个月(95%CI,9 - 27个月)。
视神经浸润是PCNSL的一种非典型且具有挑战性的表现。与玻璃体视网膜淋巴瘤相比,即使对化疗有反应,其视力和全身预后也特别差。虽然PCNSL中眼内累及很常见,临床以缓慢进展的视力恶化为特征,但淋巴瘤性ONI罕见,以迅速进展的严重视力损害为特征。